Data Sheet (Cat.No.T11408)

TargetMol

Orforglipron

Chemical Properties



CAS No. : 2212020-52-3

Formula: C48H48F2N10O5

Molecular Weight: 882.96

Appearance: no data available

Storage: store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Orforglipron (LY3502970; GLP-1 receptor agonist 1) is an orally available glucagon-like peptide (GLP-1) receptor agonist for the study of obesity and type 1 diabetes in adults.
Targets(IC50)	Glucagon Receptor
In vitro	Orforglipron potently stimulates GLP-1R-induced cAMP accumulation with partial agonist activity and no detectable recruitment of GLP-1R-mediated β-arrestin was observed[2].

Solubility Information

Solubility	DMSO: 44.15 mg/mL (50 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.1326 mL	5.6628 mL	11.3255 mL
5 mM	0.2265 mL	1.1326 mL	2.2651 mL
10 mM	0.1133 mL	0.5663 mL	1.1326 mL
50 mM	0.0227 mL	0.1133 mL	0.2265 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Ji Y, et al. Pyrazolopyridine derivative having glp-1 receptor agonist effect. WO2013046136A1.
Kawai T, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A. 2020 Nov 24;117(47):29959-29967.
Pratt E, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obes Metab. 2023 Sep;25(9):2634-2641.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481